Livatag®

Information on ReLive Trial Design and Role of its Data Safety and Monitoring Board

Paris (France), February 8, 2017 – 8.30 am CET – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, wishes to clarify information regarding the ReLive trial design and conduct and, in particular, the role of its Data Safety and Monitoring…read more →

Onxeo Completes Enrollment in Phase III Study of Livatag® for the Treatment of Hepatocellular Carcinoma

Milestone completion in line with expected preliminary outcomes mid-2017  Paris (France), Copenhagen (Denmark), January 24, 2017 – 18:30 CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the completion of enrollment in ReLive, the international Phase III clinical…read more →

Onxeo Announces 9th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that the company has received the 9th unanimous recommendation from the Data Safety Monitoring Board (DSMB), an independent European board of experts that monitors the safety of…read more →

Onxeo Announces Promising Results from Preclinical Studies of Livatag® in Pancreatic Cancer

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced encouraging results from a series of preclinical studies evaluating Livatag® interest for pancreatic cancer. Livatag® (doxorubicine Transdrug™, a nanoparticle formulation of doxorubicin) is currently being evaluated clinically…read more →

Onxeo Announces First Outcomes of Livatag® Preclinical Plan

Livatag® Nanoformulation Leads to Increased Exposure and Preferential Affinity for Liver, Supporting Current Relive Phase III Study Rationale Demonstrates Enhanced Effect in Combination with Immunotherapy  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced data from 2 in vivo studies of the Livatag® preclinical plan…read more →

Onxeo Final Data from Mechanistic Livatag® Study Show Preferential Affinity for Liver, Support Use as Advanced HCC Treatment // DANISH TRANSLATION: Endelige data fra mekanistisk studie med Livatag® viser foretrukken affinitet for leveren, hvilket understøtter brugen til behandling af fremskreden HCC

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Full results presented at AACR Annual Meeting 2016 Support continued evaluation of Livatag® in ongoing Phase III ReLive Trial  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today reported the final data from a study aiming to confirm the mechanism…read more →

Onxeo announces positive DSMB recommendation to continue Livatag® ReLive study in HCC // DANISH TRANSLATION: Onxeo offentliggør positiv anbefaling fra DSMB om at fortsætte ReLive-studiet med Livatag® mod leverkræft

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark),  – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that it has received a unanimous recommendation from the Data Safety Monitoring Board (DSMB), the independent European board of experts that monitors the safety of the Livatag® Phase III…read more →

Onxeo Poster Demonstrating Unique Livatag® Mechanism of Action Accepted for Presentation at AACR Annual Meeting // DANISH TRANSLATION: Onxeo-poster godkendt til præsentation på årsmødet i AACR: Livatag® demonstrerer unik virkningsmekanisme

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that a poster demonstrating the unique mechanism of action of Livatag® has been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, one of the…read more →

Onxeo expands collaborations to advance development program of key orphan oncology assets in combination with immuno-oncology agents // DANISH TRANSLATION: Onxeo udvider sine samarbejdsaftaler for at videreudvikle sit program med væsentlige aktiver inden for sjældne kræftsygdomme i kombination med immune-onkologiske stoffer

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Following first positive results already obtained  in several types of tumors  New partnership with CIMA’s Immunology Program and the Liver Unit at Clinica Universidad de Navarra in Spain under the leadership of Prof. B. Sangro Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan…read more →

Onxeo initiates comprehensive strategy to extend value of key orphan oncology assets // DANISH TRANSLATION: Onxeo indleder omfattende strategiplan for at øge værdien af selskabets vigtigste lægemidler til behandling af sjældne kræftsygdomme

Currently exploring combinations for synergistic effect to identify new indications for Livatag® and Beleodaq® Signed two collaborations with Lyon’s University Hospital and Synovo’s immuno-oncology specialists  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announced the initiation of a comprehensive strategy to explore further potential indications…read more →

Onxeo announces positive DSMB recommendation for continuation of Livatag® ReLive study in HCC — Onxeo offentliggør positiv anbefaling fra DSMB om at fortsætte ReLive-studiet med Livatag® mod leverkræft

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that it has received a unanimous recommendation from the Data Safety Monitoring Board (DSMB), the independent European board of experts that monitors the safety of the Livatag® Phase III trial, “ReLive”, to continue the study…read more →

Onxeo files application for key Livatag® patent — Onxeo indleverer ansøgning om vigtigt patent for Livatag®

Potential expansion of Livatag IP estate to extend commercial exclusivity through 2036 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of drugs for orphan oncology diseases, today announced that it has filed an international patent application to protect the overall compound related to its primary liver cancer orphan oncology product Livatag®. The patent…read more →

Update on ReLive, Livatag® international phase III clinical trial in HCC – 50% patients randomized – Opdatering om ReLive, det internationale kliniske fase III-studie med Livatag® til behandling af leverkræft 50% patienter randomiseret

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, updates on the clinical development status of ReLive , the Livatag® phase III trial  in the treatment of hepatocellular carcinoma. Livatag®, a new therapeutic approach for hepatocellular carcinoma Livatag® is based on the innovative « Transdrug ™ » technology  designed to formulate a chemotherapy (doxorubicin)…read more →

ReLive: investigators meeting and E-poster of the study design during the 2015 EASL congress -ReLive: Investigator-møde og e-poster om studiets design under 2015 EASL-kongressen

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that  an investigators’ meeting (on April 24, 2015) will be held during the 50th annual meeting of the European Association for the Study of the Liver (EASL) taking place in Vienna (Austria) from April 22 to April 26, 2015, with…read more →

Onxeo announces 6th positive DSMB recommendation for Livatag® ReLive study in HCC – Onxeo offentliggør den sjette positive anbefaling fra ekspertkomité for ReLive-studiet med Livatag® mod primær leverkræft

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that the independent European board of experts, the Data Safety Monitoring Board (“DSMB”), which monitors the safety of the Livatag® phase III trial, “ReLive”, has once again unanimously recommended to continue the study without modification. ReLive is an international, randomized…read more →

12